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Abstract 
The RET proto-oncogene has not only conclusively been identified as responsible for the 
three subtypes of the inherited cancer syndrome multiple endocrine neoplasia type 2 
(MEN-2) but also shown to be involved in the molecular evolution of sporadic medullary 
and papillary thyroid carcinoma as well as Hirschsprung's disease. A variety of recent 
studies have elucidated the pathophysiological mechanisms leading to neoplastic disease 
and we now understand that dominant activating germline mutations lead to MEN-2A, 
MEN-2B, and familial MTC; somatic mutations to sporadic medullary thyroid carcinoma; 
RET rearrangements to papillary thyroid carcinoma; and inactivating alterations to 
Hirschsprung's disease. The clinical significance, however, of RET alterations especially in 
sporadic thyroid tumors is still controversial and therapeutic concepts in MEN-2 gene 
carriers only start to emerge. This article is a short summary of the recent findings on the 
structure and physiology of the RET proto-oncogene and its role in familial and sporadic 
thyroid cancer. 
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Introduction 
There have been many recent advances 
in our understanding of thyroid disease, 
including the molecular biology of thyroid 
neoplasms. Recent reports have described 
the involvement of specific genetic alter- 
ations in different ypes of thyroid neo- 
plasms:/?as point mutations are frequently 
observed in tumors with follicular histol- 
ogy and a high prevalence of p53 point 
mutations have been found in anaplastic 
carcinomas. More recent studies revealed 
that the RETproto-oncogene is involved in 
the tumorigenesis of medullary thyroid 
carcinoma (MTC) and papillary thyroid car- 
cinoma by activation of its tyrosine kinase 
either by point mutation or rearrangement. 
The RET Proto-Oncogene 
The PETproto-oncogene (REarranged 
duringTransfection) is located on chromo- 
some 10ql 1.2, has 21 exons, and encodes 
a transmembrane receptor with cytoplas- 
mic tyrosine kinase activity [1]. PETtran- 
scripts and protein are expressed in cells 
and neoplasms of neuroendocrine differ- 
entiation, including parafollicular C cells 
and MTCs, adrenal medulla nd pheochro- 
mocytomas well as neuroblastomas, par- 
athyroid parenchymal cell precursors and 
peripheral nerves, neurofibromas, and 
schwannomas. The PETprotein is a func- 
tional receptor for the glial-cell-line-derived 
neurotrophic factor (GDNF), a distant 
member of the transforming growth fac- 
tor (TGF)-~ superfamily [2]. GDNF uses 
a multisubunit receptor system in which 
the GDNF receptor-iX (GDNFR-Ix) and 
RET function as the ligand-binding and 
signaling components, respectively [3]. 
RET in Medullary Thyroid Carcinoma 
Several groups have demonstrated that 
distinct germline mutations in the PET 
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proto-oncogene are associated with the 
dominantly inherited cancer syndromes 
multiple ndocrine neoplasia type 2A and 
2B (MEN-2A and MEN-2B) and familial 
medullary thyroid carcinoma (FMTC) [4]. 
All three syndromes share heritable MTCs 
as part of the disease phenotype [5]. 
MEN-2A, which accounts for more than 
90% of all cases of MEN-2, is characterized 
by the additional occurrence of pheochro- 
mocytoma and hyperparathyroidism resulting 
from parathyroid hyperplasia or adenoma. 
Activating mutations in the cysteine-rich 
extracellular region cause nhanced dimeriza- 
tion of the RETtyrosine kinase receptor and 
autophosphorylation, a d are causative for 
MEN-2A and FMTC. Missense germline 
mutations in one of six codons for Cys in 
RETexons 10 (609, 611,618, and 620) 
and 11 (630 and 634) have been identi- 
fied in 97% of MEN-2A and 87% of 
FMTC families [4]. In FMTC families 
MTC is the only clinical feature and the 
course of the disease is more benign than 
that of MEN-2A or MEN-2B. In a few 
FMTC families, additional germline 
mutations have been identified at codons 
768 and 804 in RETexons 13 and 14. The 
effects of these mutations are unclear. The 
former may alter kinase activity by chang- 
ing the substrate specificity or the ATP- 
binding capacity of the receptor and the 
latter may activate the receptor by altering 
its interactions with normal cellular sub- 
strates or modifying the range ofsubstrates 
the receptor can phosphorylate. In
MEN-2B, which accounts for approx 5% 
of all patients with MEN-2, an activating 
mutation of the tyrosine kinase core 
domain has been identified in 94% of cases. 
This mutation at codon 918 in exon 16 
replaces methionine with threonine and 
causes increased autophosphorylation and
alteration of the substrate specificity of the 
tyrosine kinase. The MEN-2B syndrome 
is characterized by MTC and pheochro- 
mocytoma, rare involvement of parathy- 
roids, myelinated corneal nerves, gas- 
trointestinal ganglioneuromatosis, anda 
variety of skeletal abnormalities such as a 
marfanoid habitus, pes cavus, talipes 
equinovarus, lipped capital femoral epi- 
physis, kyphosis, scoliosis, and an increased 
joint laxity [5]. The thyroid tumors tend 
to occur at an earlier age and pursue amore 
aggressive course than in patients with 
MEN-2A and FMTC. The germline 
mutation in MEN-2B frequently repre- 
sents new mutations (approx 50%) and it 
appears that the mutant allele is paternally 
derived, even though the father does not 
carry a germ line mutant allele. 
Somatic mutations in PET have also 
been found in a proportion of patients with 
sporadic MTCs. By far the most common 
mutation involves codon 918 (Met --+ 
Thr). This type of missense mutation in 
exon 16 has been described in 23-85% of 
sporadic MTCs; in our own series of 16 
examined tumors we found 44% MTCs 
harboring this type of PET mutation [6]. 
Other groups found additional mutations 
at codon 768 ofexon 13, at codon 883 of 
exon 15, at codon 634 of exon 11, and in 
exon 10 in a small proportion of tumors 
[4]. Furthermore, microdeletions causing 
the loss of a Cys residue at codon 630 or 
634 have been described in sporadic MTCs 
by several groups. The differences in 
mutational frequencies and codons involved 
that have been reported by various centers 
suggest that either egional and environ- 
mental or technical factors might be 
involved. Thus, in a recent study, Eng et 
al. [7] examined microdissected subpopu- 
lations from sporadic MTCs and multiple 
metastases from these tumors and found 
that approx 80% of sporadic MTCs had 
at least one subpopulation with the PET 
codon 918 mutation. The distribution of 
this mutation was nonhomogeneous, 
occurring only in subpopulations i  most 
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tumors and among subsets of multiple 
metastases. These findings suggest either 
that the codon 918 mutation can arise as 
an event in progression within a metastatic 
clone, or that MTC can be of polyclonal 
origin. In the same study the authors also 
reported that one of two MTCs from 
MEN-2A patients carried a somatic muta- 
tion at codon 918 in addition to the PET 
mutation present in the germline. 
Recently, two groups have reported that 
somatic mutations of the RET proto- 
oncogene in sporadic MTCs were signifi- 
cantly correlated with a poor outcome, 
whereas others have demonstrated that he 
presence or absence of the somatic muta- 
tion at the PETcodon 918 was not corre- 
lated with clinical data, including most 
recent follow-up [8,9]. Thus, the clinical 
significance ofPETmutations insporadic 
MTCs remains to be elucidated on larger 
series of patients with long-time follow- 
up data. 
We and others have demonstrated that 
the analysis of germline DNA for PET 
mutations may be helpful to determine the 
hereditary orsporadic nature of MTCs [10] 
and that DNA analysis can also be per- 
formed on DNA extracted from paraffin- 
embedded tissues [11]. The absence of a 
germline PETexon 10, 11, 13, 14, or 16 
mutation appears to rule out MEN-2A, 
MEN-2B, or FMTC to a high probability, 
although a familial form of MTC other 
than classical MEN-2 cannot be excluded 
conclusively. Furthermore, the presence of 
a few MEN-2 families without detectable 
PET mutations indicate that this disease 
might also be caused by germline muta- 
tions in the gene encoding the GDNFR-0c 
or other genes. 
RET in Papillary Thyroid Carcinoma 
The PETproto-oncogene has also been 
implicated in the causation of papillary 
thyroid carcinoma (PTC). It has been 
shown that RET is activated through 
somatic rearrangements in a subset of 
PTCs. The RET/PTC oncogenes, rearranged 
forms of the RETproto-oncogene, encode 
fusion proteins in which proto-RET 
tyrosine kinase and C-terminal domains are 
fused to different donor genes. The respec- 
tive RET/PTC oncoproteins display con- 
stitutive tyrosine kinase activity and 
tyrosine phosphorylation. Three major 
forms of the RET/PTC oncogene have 
been identified: the RET/PTC- 1 oncogene 
(where c-RET rearranges with the H4 
gene D10S170 on chromosome 10q21), 
the RET/PTC-2 oncogene (where c-PET 
rearranges with the regulatory subunit R1 
alpha of the protein kinase A on 17q23), 
and the RET/PTC-3 oncogene (where 
c-PETrearranges with the RFG2/Elel gene 
on 10ql 1.2). Thus, the two most common 
forms, PET/PTC-1 and RET/PTC-3, both 
result from a paracentric nversion of the 
long arm of chromosome 10 [12]. More 
recently, a novel type ofHel/pETrearrange- 
ment designated PET/PTC-4 has been 
described in which the exon 5 of Elel is 
joined to exon 11 instead ofexon 12 of PET 
and the cDNA sequence is93 nucleotides 
larger than the regular one [13]. The PET/ 
PTC-4 oncogene has been found in a 
post-Chernobyl PTC, indicating that tar- 
geted radiation effects could be responsible 
for the atypical PETrearrangement. 
Wide differences (2.5-60%) in fre- 
quency of PETactivation by PET/PTC in 
PTCs of different populations have been 
reported, and it is not clear whether these 
are owing to environmental f ctors, racial 
differences, or technical reasons. However, 
several studies have shown an association 
between ionizing radiation and development 
of PTC. In addition, in vitro irradiation of 
tumor cell lines induced rearrangements of 
PET similar to those observed in human 
PTCs. These two observations could be 
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related to the reported increased incidence 
of PTCs in children living in contami- 
nated areas around Chernobyl. However, 
it has recently been demonstrated that age, 
perse, also plays a role in the development 
ofRETpositive PTCs [14]. Furthermore, 
it has been shown that RET/PTC activa- 
tion is present in 11 of 26 (42%) occult 
PTCs and therefore concluded that _gET/ 
PTC rearrangement represents an early 
event in the process of thyroid cell trans- 
formation [15]. 
The clinical relevance of RET/PTC 
rearrangements in PTCs is controversial. 
Some have suggested that RET/PTC 
expression could serve as an indicator of 
aggressive b havior in PTCs, specifically for 
distant metastatic disease. In a recent study, 
Sugg et al. [16] analyzed 60 thyroid carci- 
nomas by RT-PCR for RET/PTC expres- 
sion to determine a possible correlation 
with clinical data or tumor morphology. 
They found RET/PTC oncogene rear- 
rangements in 3 of 60 (5%) PTCs of young 
patients (<45 yr of age) with small thyroid 
carcinomas showing a predisposition for 
lymphatic involvement, suggesting a pos- 
sible role in the development of this sub- 
group of tumors. Thus, more data are 
necessary to determine whether molecular 
analysis of RET/PTC rearrangements are
required in patients with PTCs. 
In addition to the tumor types men- 
tioned, PET appears also to be causative 
for 10-40% of cases with Hirschsprung's 
disease [17] with or without MEN-2 [18], 
but seems not to be generally important in
the formation of sporadic neuroendocrine 
tumors other than MTC and pheochro- 
mocytoma [6]. 
Summary and Conclusion 
A variety of recent studies on the RET 
proto-oncogene have elucidated the patho- 
physiological mechanisms leading to neo- 
plastic disease; we now understand that 
dominant activating ermline mutations 
lead to MEN-2A, MEN-2B, and FMTC; 
somatic mutations to sporadic MTCs; 
RETrearrangements to PTCs; and inacti- 
vating alterations to Hirschsprung's disease. 
The clinical significance of RETalterations, 
especially insporadic thyroid tumors, how- 
ever, is still controversial nd therapeutic 
concepts in MEN-2 gene carriers only start 
to emerge. Furthermore, a substantial pro- 
portion of sporadic MTCs and especially 
PTCs do not show RET mutations or 
activation and are likely caused by other 
genetic alterations. Several candidate genes, 
such as the GDNF and GDNFR-ot [19], 
are currently under investigation a d it is 
anticipated that the near future will bring 
new insights into the tumorigenesis of
sporadic as well as hereditary thyroid 
carcinoma. 
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